Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OPTHEA LIMITED

Home Clinical Trial Sponsors and OrganizationsOPTHEA LIMITED

OPTHEA LIMITED

403/650 CHAPEL STREET, South Yarra, Victoria, Australia

Also known as:

circadian technologies limited

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

31

19 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

21

67.7%

Phase 3

9

29.0%

Phase 2

1

3.2%

Trial Status Distribution

Active, not recruiting

18

58.1%

Completed

5

16.1%

Not yet recruiting

1

3.2%

Recruiting

5

16.1%

Terminated

2

6.5%

Clinical Trials

Trials sponsored by this organization (31)

A clinical study to compare the safety and effectiveness of study drug OPT-302 in combination with ranibizumab, compared with ranibizumab alone in participants who have age related loss of vision in the central part of their eye.

Oct 2021990 participants

A clinical study to compare the safety and effectiveness of study drug (OPT-302) in combination with aflibercept, compared with aflibercept alone who have age related loss of vision in the central part of their eye.

Oct 2021990 participants

A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneratio

Active, not recruiting

Oct 2021990 participants

A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneratio

Active, not recruiting

Aug 2021990 participants

A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneratio

Active, not recruiting

Aug 2021990 participants

A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneratio

Active, not recruiting

Jul 2021990 participants

A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneratio

Active, not recruiting

Jul 2021990 participants

A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneratio

Active, not recruiting

Jul 2021990 participants

Page 1 of 4

Approvals

No approval data available

News

Sozinibercept Shows Promise in Wet AMD Treatment as Opthea's Pivotal Trials Progress

- Opthea's sozinibercept (OPT-302) demonstrates potential to enhance visual outcomes in wet age-related macular degeneration patients without competing with standard anti-VEGF-A therapies. - The company's crucial COAST and ShORe trials are advancing on schedule, with results anticipated in early and mid-2025, leading to potential regulatory filing in Q1 2026. - Leading analysts, including Leerink Partners' Marc Goodman, maintain bullish outlook on Opthea's stock, highlighting the drug's commercial promise in addressing unmet needs in ophthalmology.

On this page

Overview
Clinical Trials31
Approvals
News1

Back to Organizations